Table 2.
Virologic suppression, CD4 cell count, and CD4% by visit during bictegravir/emtricitabine/tenofovir alafenamide treatment.
| B/F/TAF (N = 33) | |
| HIV-1 RNA <50 copies/ml [n/N (%)]a | |
| Baseline | 33/33 (100) |
| Week 12b | 23/23 (100) |
| Delivery | 32/32 (100) |
| Week 6 postpartum | 32/32 (100) |
| Week 12 postpartum | 32/32 (100) |
| Week 18 postpartumc | 32/32 (100) |
| CD4 cell count (cells/μl) [median (Q1, Q3)] | |
| Baseline | 558 (409, 720) |
| Week 12 postpartumc | 636 (491, 1026) |
| Change from baseline to week 12 postpartumd | 159 (27, 296) |
| CD4% [median (Q1, Q3)] | |
| Baseline | 32.3 (27.0, 40.2) |
| Week 12 postpartumc | 32.5 (29.2, 37.9) |
| Change from baseline to week 12 postpartumd | 0.1 (−2.3, 4.2) |
a
Missing = excluded analysis. The denominator for the percentages is the number of adult participants with nonmissing HIV-1 RNA value at each visit.
b
Visit performed 12 weeks after baseline, which could have been in the second or third trimester depending on the participant's enrollment date.
c
While prespecified windows for reporting advanced in 6-week intervals, actual data in week 18 postpartum identifier consist of 15–17 weeks postpregnancy follow-up, in alignment with protocol plan of 16 weeks of follow-up.
d
n = 31.
B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; Q, quartile.